Drugs / GXHPC1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04088058 | Nov 2019 → Apr 2025 | cirrhosis of liver | Gwo Xi Stem Cell Applied Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GXHPC1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04088058 ↗ |
| Modality | Cell therapy | “autologous ADSCs” NCT04088058 ↗ |
| Route | Other | “injected intrahepatically” NCT04088058 ↗ |